Table 6.
Type of treatment, relapses, histopathological and laboratory findings of Crohn's disease patients
| CDAI (mean ± SD) | 108.21 ± 53.84 |
| CDAI (median/minimum/maximum) | 103.33/38/259.5 |
| Treatment used: (single drug or combinations) oral 5-ASA ± Metronidazole, ciprofloxacin, azathioprine, prednisone, infliximab, | |
| surgical interference (yes/no) | 7/15 |
| Relapses (mean ± SD) | 1.68 ± 2.21 |
| Relapses (median/minimum/maximum) | 1/0/8 |
| Malignant transformation | None |
| Mean ESR 1st hour (mean ± SD) | 49.52 ± 30.98 |
| CRP (positive/negative) | 17/5 |
| ANCA (positive/negative/not done) | 6/16 |
| ASCA (positive/negative) | 4/18 |
| Pathological findings included: cellular infiltrate, focal inflammation, microfisttulization, non caseating granulomas, cobblestoning, lymphoid hyperplasia | |
| Pathology (diagnostic/suggestive/non conclusive) | 7/8/7 |
| Mean hemoglobin concentration, gm/dL (mean ± SD) | 11.95 ± 2.14 |
| Mean PLT count (mean ± SD) | 296272.72 ± 146308.60 |
| Mean TLC (mean ± SD) | 7868.57 ± 2708.17 |
CDAI: Crohn’s disease activity index; ASA: Aminosalicylic acid; CRP: C-reactive protein; ANCA: Anti-neutrophil cytoplasmic antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies.